NVAX
Biotechnology · Healthcare
Equibles does not estimate personal net worth.
Get an email with a short summary when Novavax Inc publishes a filing, an earnings call transcript or a press release.
Get NVAX alertsThe proxy statement of Novavax Inc reports total compensation of $3,688,276 for Elaine O'Hara in fiscal 2025, including a base salary of $561,080. Disclosed compensation is on record for 2 fiscal years. Elaine O'Hara has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Novavax Inc on November 17, 2026. Novavax Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Novavax Inc includes John C. Jacobs (CEO and Board Member), James P. Kelly (CFO), John J. Trizzino (CFO and COO) and 7 others.
“At the macro level, we're really very excited about the commitment that Sanofi has shown since we entered into our collaborative license agreement back in 2024.”
“As discussed, one of the clearest indicators that our strategy is working is the momentum we're seeing across our partnerships. We are focused on two objectives, maximizing value from our existing collaborations while building the next generation of licensing opportunities.”
Source not stated
NVAX
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Novavax Inc (NVAX) | EVP, Chief Strategy Officer | $561,080 | $3,688,276 |
| 2024 | Novavax Inc (NVAX) | EVP, Chief Strategy Officer | $535,600 | $1,638,116 |